Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Penicillamine
Drug ID BADD_D01709
Description Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.
Indications and Usage For treatment of Wilson's disease, cystinuria and active rheumatoid arthritis.
Marketing Status approved
ATC Code M01CC01
DrugBank ID DB00859
KEGG ID D00496
MeSH ID D010396
PubChem ID 5852
TTD Drug ID D08HZC
NDC Product Code 59285-014; 76339-159; 0254-2000; 68682-020; 70010-907; 0591-4171; 68022-7041; 72640-012; 25010-705; 60505-4696; 62559-970; 71205-916; 0037-4401; 62207-013; 71052-491; 43598-634; 51991-974; 70748-153; 42973-230; 51552-1096; 49884-146; 68475-201; 59651-245; 70159-004; 76003-0870
UNII GNN1DV99GX
Synonyms Penicillamine | Mercaptovaline | D-Penicillamine | D Penicillamine | Dimethylcysteine | beta,beta-Dimethylcysteine | beta,beta Dimethylcysteine | D-3-Mercaptovaline | D 3 Mercaptovaline | Metalcaptase | Cuprimine | Copper Penicillaminate | Penicillaminate, Copper | Cuprenil
Chemical Information
Molecular Formula C5H11NO2S
CAS Registry Number 771431-20-0
SMILES CC(C)(C(C(=O)O)N)S
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Lichen planus23.03.08.001--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.0030.000113%
Monocytosis01.02.01.004--Not Available
Motor neurone disease17.05.05.002--Not Available
Mouth ulceration07.05.06.004--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myasthenia gravis17.05.04.001; 10.04.05.001; 15.05.08.0010.000051%
Nausea07.01.07.0010.000139%
Nephrotic syndrome20.05.01.0020.000051%
Neuropathy peripheral17.09.03.003--Not Available
Obliterative bronchiolitis22.03.01.012; 12.02.09.036; 10.02.01.096--Not Available
Optic neuritis10.02.01.097; 17.04.05.001; 06.04.08.002--Not Available
Pancreatitis07.18.01.001--
Pancytopenia01.03.03.003--Not Available
Papule23.03.03.038--Not Available
Pemphigoid23.03.01.004; 10.04.02.002--Not Available
Pemphigus23.03.01.005; 10.04.02.003--Not Available
Peptic ulcer07.04.07.001--Not Available
Peripheral sensory neuropathy17.09.03.005--
Polymyositis15.05.01.004; 10.04.05.004--Not Available
Premature baby18.04.02.0010.000051%Not Available
Proteinuria20.02.01.011--
Pruritus23.03.12.001--
Pulmonary alveolar haemorrhage22.01.02.005; 24.07.01.0150.000051%Not Available
Pulmonary fibrosis22.01.02.006--
Rash23.03.13.0010.000164%Not Available
Rash erythematous23.03.13.029--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene